Unique ID issued by UMIN | UMIN000046999 |
---|---|
Receipt number | R000053619 |
Scientific Title | Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients |
Date of disclosure of the study information | 2022/12/01 |
Last modified on | 2023/04/14 18:53:29 |
Humoral response after BNT162b2 vaccine in Japanese of hemodialysis patients
Effectiveness of BNT162b2 vaccine in hemodialysis patients
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Effectiveness of BNT162b2 vaccine in Japanese hemodialysis patients
Japan |
Hemodialysis patients
Nephrology |
Others
NO
Effectiveness of BNT162b2 vaccine in hemodialysis patients
Safety
Others
Acquisition rate of SARS-CoV-2 IgG antibody after BNT162b2 vaccination
Adverse events of BNT162b2 vaccine
Observational
18 | years-old | <= |
Not applicable |
Male and Female
Patients undergoing hemodialysis at our hospital
Patients with no history of COVID-19
185
1st name | RYOICHI |
Middle name | |
Last name | MIYAZAKI |
Fujita Memorial Hospital
Internal Medicine
910-0004
4-15-7, Hounaga, Fukui City, Fukui Prefecture
0776-21-1277
ryoichi@mitene.or.jp
1st name | RYOICHI |
Middle name | |
Last name | MIYAZAKI |
Fujita Memorial Hospital
Internal Medicine
910-0004
4-15-7, Hounaga, Fukui City, Fukui Prefecture
0776-21-1277
http://www.fujita-mhp.jp/
ryoichi@mitene.or.jp
Fujita Memorial Hospital
Fujita Memorial Hospital
Self funding
Japan
Fukui General Hospital
58-16-11, Egami-cho, Fukui City, Fukui Prefecture
0776-59-1300
chiey@mx3.fctv.ne.jp
NO
藤田記念病院(福井県)
2022 | Year | 12 | Month | 01 | Day |
Unpublished
https://rrtjournal.biomedcentral.com/
185
The anti-SARS-CoV-2 IgG antibody positivity rate after BNT162b2 vaccine administration was 181/185 = 97.8% in the hemodialysis patients.The median antibody titer in hemodialysis patients was 2728.7 AU/mL, with a quartile range of 1024.2-7688.2 AU/mL.Adverse events associated with vaccine administration were mild.
2022 | Year | 02 | Month | 24 | Day |
2022 | Year | 12 | Month | 01 | Day |
The age of the patients was 68.7+-12.0 years, 125 were males and 87 were females. The dialysis vintage was 106+-60 months. Diabetes mellitus was the primary disease in 72 patients.
Patient inclusion was completed on October 22, 2022.
The most common adverse event was pain at the vaccination site (65.4%), but others were mild.
The anti-SARS-CoV-2 IgG antibody positivity rate after BNT162b2 vaccine administration was 181/185 = 97.8%
Terminated
2021 | Year | 04 | Month | 14 | Day |
2021 | Year | 05 | Month | 12 | Day |
2021 | Year | 05 | Month | 13 | Day |
2022 | Year | 02 | Month | 28 | Day |
2022 | Year | 02 | Month | 28 | Day |
2022 | Year | 02 | Month | 28 | Day |
2022 | Year | 02 | Month | 28 | Day |
Two doses of BNT162b2 vaccine were administered to hemodialysis patients at a 3-week sensory interval, followed by a survey of SARS-CoV-2 IgG antibody titers approximately 2 weeks later.
2022 | Year | 02 | Month | 24 | Day |
2023 | Year | 04 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053619
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |